1. Introduction
===============

The small family of the Calycanthaceae comprises four genera, namely *Chimonanthus* Lindley, *Sinocalycanthus* Cheng & S. Y. Chang, *Calycanthus* L., and *Idiospermum*, which globally include *ca*. 15 species \[[@B1-molecules-20-06715],[@B2-molecules-20-06715],[@B3-molecules-20-06715]\]. The plants of the *Chimonanthus* and *Sinocalycanthus* genera are ornamental shrubs endemically distributed in China, and those of the *Calycanthus* and *Idiospermum* originate from North America and Australia, respectively. The classification of the species of *Chimonanthus* genus is still a tough task and has been a subject of debate for a long time \[[@B4-molecules-20-06715]\]. The early literature categorized this genus into three species, *i.e.*, *Ch. nitens* Oliv., *Ch. praecox* (Linn.) Link, and *Ch. salicifolius* S.Y. Hu \[[@B5-molecules-20-06715]\]. Recently it was proposed that this genus be classified in 10 species based on morphological evidence, including *Ch. nitens* Oliv., *Ch. praecox* (Linn.) Link, *Ch. salicifolius* S.Y. Hu, *Ch. nitens*, *Ch. zhejiangensis* M.C. Liu, *Ch. campanulatus*, *Ch. baokangensis*, *Ch. anhuiensis*, *Ch. caespitosa*, *Ch. campanulatus* var. guizhouensis \[[@B6-molecules-20-06715]\]. In addition, only one species, *C. chinensis* Cheng et S.Y. Chang, is attributed to the *Sinocalycanthus* genus. Three plants named *C. floridus* var. floridus, *C. floridus* var. laevigatus, and *C. occidentalis* Hook. et Arn. pertain to the genus *Calycanthus*. The plant *Idiospermum australiense* (Diels) S. T. Blake a rare tree that occurs only in the North Queensland region of Australia is the sole member of the *Idiospermum* genus. These Calycanthaceae plants are primitive angiosperms and popular ornamental flowers with a pleasant aroma. The Calycanthaceae plants have long been used in Traditional Chinese Medicines (TCMs), to treat rheumatic arthritis, coughs, throat wounds, dizziness, nausea, fever, detoxification, and enteral disease \[[@B7-molecules-20-06715],[@B8-molecules-20-06715],[@B9-molecules-20-06715]\].

The chemical investigation of the Calycanthaceae plants started more than one hundred years ago in 1888, which led to the isolation of a large amount of alkaloids, flavonoids \[[@B10-molecules-20-06715]\], lignans \[[@B6-molecules-20-06715],[@B11-molecules-20-06715]\], coumarins \[[@B12-molecules-20-06715],[@B13-molecules-20-06715],[@B14-molecules-20-06715]\], terpenoids \[[@B15-molecules-20-06715],[@B16-molecules-20-06715],[@B17-molecules-20-06715]\], and essential oils \[[@B7-molecules-20-06715],[@B18-molecules-20-06715],[@B19-molecules-20-06715],[@B20-molecules-20-06715]\]. It is important to note that the discovery of the Calycanthaceae alkaloids was reminiscent of the history of development of science. Looking back to this history, only 14 alkaloids ([Figure 1](#molecules-20-06715-f001){ref-type="fig"}) whose discoveries were full of hardship and arduousness were characterized from this family. During past decades, there has been a trend towards e synthetic approaches of these structurally interesting and bioactive alkaloids. This review attempts to provide timely and comprehensive coverage of the chemical and biological studies related to the Calycanthaceae alkaloids, with a specific focus on summarizing the great amount of synthetic work performed in this area.

2. Structures, Biological Activities, and Biosynthetic Origins of Calycanthaceae Alkaloids
==========================================================================================

2.1. Structures of Calycanthaceae Alkaloids and Their Discovery
---------------------------------------------------------------

The phytochemical investigation of the plants Calycanthaceae was first described in 1888, which led to isolation of the first Calycanthaceae alkaloid, (+)-calycanthine (**1**, [Figure 1](#molecules-20-06715-f001){ref-type="fig"}) with a dimeric piperidinoquinoline skeleton, from the seeds of *C. glaucus* Willd. by Eccles. One year later, Wiley proved the high content of this alkaloid in the seeds of the same plant \[[@B21-molecules-20-06715]\]. In 1905, further progress was made by Gordin whereby this principal alkaloid was crystalized in different forms at ordinary temperature and deduced to possess a molecular formula C~11~H~14~N~2~ containing no oxygen atom \[[@B21-molecules-20-06715],[@B22-molecules-20-06715]\]. A few years later, Späth and Stroh expressed their disagreement on Gordin's work and stated that the empirical formula of (+)-calycanthine should be doubled C~11~H~14~N~2~ \[[@B23-molecules-20-06715]\]. Soon Manske put forward the possibility that this molecular formula might be C~22~H~26~N~4~ \[[@B24-molecules-20-06715]\], which was finally proved by Barger's group in 1939 \[[@B25-molecules-20-06715]\]. The structure of this alkaloid (+)-calycanthine, C~22~H~26~N~4~, was finally established uniequivocally by means of X-ray crystal structural analysis of its dihydrobromide dehydrate by Hamor's group in 1960 \[[@B26-molecules-20-06715]\].

![Structures of the Calycanthaceae alkaloids.](molecules-20-06715-g001){#molecules-20-06715-f001}

In 1905, Gordin also reported a second alkaloid, isocalycanthine, from the seeds of *Chimonanthus* genus, which possessed a different melting point and showed different behavior with respect to the removal of water of crystallization from the hydrated base with those of calycanthine \[[@B27-molecules-20-06715],[@B28-molecules-20-06715]\]. However, Manske expressed doubts about the existence of isocalycanthine. In his study on the species of *C. floridus* L., a great quantity (1.2%) of calycanthine was. Gordin's seed extract consisted in reality of *C. fertilis*. In the same report, Gordin also discribed the isolation process of (+)-calycanthine (2.6%) from the seeds of *Meratia praecox* (*C. praecox*) \[[@B24-molecules-20-06715]\]. In 1992, the occurrence of isocalycanthine in a closely related species *Psychotria forsteriana* (Rubiaceae) was reported by Kuballa's group \[[@B29-molecules-20-06715]\].

In 1938, Barger's group isolated a minor alkaloid, (−)-calycanthidine (**2**), from the seeds of *C. floridus*, which molecular formula was deduced to be C~13~H~16~N~2~ \[[@B30-molecules-20-06715]\]. This conclusion was corrected by Saxton in 1962, who established both the formula C~23~H~28~N~4~ and the structure of (−)-calycanthidine \[[@B31-molecules-20-06715]\]. The alkaloid (−)-chimonanthine (**3**) was firstly obtained from *Ch. fragrans*. Lindle (*Ch. praecox*) by Hodson's group \[[@B32-molecules-20-06715]\], and its structure was determined on the basis of detailed X-ray analysis of chimonanthine dihydrobromide by Grant's group \[[@B33-molecules-20-06715],[@B34-molecules-20-06715]\]. As for (−)-folicanthine (**4**), it was first isolated by Hodson's group in 1957 and was identified to be a dimeric pyrrolidinoindoline alkaloid, close to (−)-calycanthidine (**2**), and (−)-chimonanthine (**3**) \[[@B32-molecules-20-06715]\]. From then on, this seemed to be an end for the structural elucidation of (−)-calycanthidine, (−)-chimonanthine, (−)-folicanthine, until in 2000, the total syntheses of these alkaloids were completed by Overman's group, proving that (−)-calycanthidine, (−)-chimonanthine, (−)-folicanthine should be drawn as compounds **2**, **3**, and **4** ([Figure 1](#molecules-20-06715-f001){ref-type="fig"}), respectively; therefore the structures of compounds *ent*-**2**, *ent*-**3**, and *ent*-**4** reported in the previous papers should be (+)-calycanthidine, (+)-chimonanthine, (+)-folicanthine, respectively \[[@B35-molecules-20-06715]\]. Calycanine (**5**) with a molecular formula C~16~H~10~N~2~ was a product of calycanthine and chimonanthine obtained by Zn dehydrogenation. Its structure was first incorrectly proposed by Barger, and then revised by Woodward's group via synthesis \[[@B32-molecules-20-06715],[@B34-molecules-20-06715],[@B36-molecules-20-06715]\].

(−)-Idiospermuline (**6**), a trimeric pyrrolidinoindoline, together with two known dimeric alkaloids, (+)-calycanthine and (−)-chimonanthine were isolated by the bioassay-guided method from the seeds of *Idiospermum australiense* (Diels) S.T. Blake, a native species from North Queensland, Australia. The structure of (−)-idiospermuline was determined by NMR and MS data and the absolute stereochemistry was established by X-ray crystallographic study of idiospermuline trimethiodide (**6a**) \[[@B37-molecules-20-06715]\].

In 2004, Takayama's group investigated the alkaloidal constituents of the seeds of *Ch. praecox* L., leading to the isolation of two new tryptamine-related alkaloids, chimonamidine (**7**) and chimonanthidine (**8**), together with the known (+)-calycanthine, (−)-chimonanthine, (−)-folicanthine, and (−)-calycanthidine. They conducted the total synthesis of (±)-chimonamidine to establish its absolute structure. As a result, natural chimonamidine showed optical rotation $\left\lbrack \alpha \right\rbrack_{D}^{19}$ = −12.6, which was significantly different with those of (*R*)-(−)-chimonamidine ($\left\lbrack \alpha \right\rbrack_{D}^{23}$ = −178) and (*S*)-(+)-chimonamidine ($\left\lbrack \alpha \right\rbrack_{D}^{23}$ = +171), suggesting that natural chimonamidine is a mixture slightly enriched with the (*R*)-(−)-enantiomer. Chimonanthidine (**8**) was determined to be *N*~b~-monodemethylfolicanthine by total synthesis, with the absolute configuration eventually confirmed by a combined strategy of comparing the CD spectrum with that of known (−)-folicanthine \[[@B38-molecules-20-06715]\]. In his paper of 2006, a further phytochemical study on the seeds and rinds of *Ch. praecox* (L.) f. concolor resulted in the isolation of a new pyrrolidinoindoline-type alkaloid, CPC-1 (**9**), and one new tetrahydroquinoline dimeric alkaloid, CPC-2 (**10**), together with eight known alkaloids, (+)-calycanthine, (−)-chimonanthine, (−)-folicanthine, (−)-calycanthidine, (−)-chimonanthidine, *meso*-chimonanthine (**11**), tryptamine (**12**), and *N*~a~,*N*~b~-dimethyltryptamine (**13**) \[[@B39-molecules-20-06715]\].

In 2009, an antifungal activity-guided phytochemical investigation on the defatted seeds of *Ch. praecox*, a species grown in Shaanxi Province of China, afforded two dimeric alkaloids, (+)-calycanthine and (−)-folicanthine \[[@B40-molecules-20-06715]\]. Additionally, an additional indole-derived glycoside, 3-methylcarboxymethyl-indole-1-*N*-β-[d]{.smallcaps}-glucopyranoside (**14**), and the four known compounds (+)-calycanthine, (−)-chimonanthine, (−)-folicanthine, (−)-calycanthidine were obtained from the fruits and leaves of *C. praecox* in 2011 \[[@B15-molecules-20-06715]\]. A recent phytochemical study on the flower buds of *Ch. praecox* also led to the isolation of five known dimeric alkaloids and several other compounds \[[@B41-molecules-20-06715]\].

2.2. Biological Activities
--------------------------

The Calycanthaceae plants have been used as Traditional Chinese Medicines (TCMs) for the treatment of colds, and as sedative, antitussive, anti-hypertension, antioxidation, anti-inflammatory, and antitumor medicines \[[@B14-molecules-20-06715],[@B15-molecules-20-06715]\]. As the important components of these plants, the Calycanthaceae alkaloids showed biological activities such as anti-convulsant, anti-fungal, anti-viral, analgesic, anti-tumor, and melanogenesis inhibitory properties.

The main representative alkaloid, calycanthine (**1**), has been recognized as a powerful centrally acting anti-convulsant for a long time \[[@B42-molecules-20-06715],[@B43-molecules-20-06715]\]. It was reported that calycanthine may mediate its convulsant action predominantly by inhibiting of the inhibitory neurotransmitter GABA as a result of interactions with [l]{.smallcaps}-type Ca^2+^ channels and by inhibiting GABA-mediated chloride currents at GABA~A~ receptors \[[@B44-molecules-20-06715]\].

(+)-Calycanthine (**1**) and (−)-folicanthine (**4**) were evaluated for their antifungal activities against five plant pathogenic fungi, *Exserohilum turcicum*, *Bipolaris maydis*, *Alternaria solani*, *Sclerotinia sderotiorum*, and *Fusarium oxysportium*. It turned out to be that *B. maydis* was the most susceptible to **1** with an EC~50~ value of 29.3 μg/mL, and then *S. sderotiorum* to **4** with an EC~50~ of 61.2 μg/mL \[[@B40-molecules-20-06715]\]. (−)-Chimonanthine (**3**) and (−)-folicanthine (**4**) also showed weak antiviral activities against porcine respiratory and reproductive syndrome virus (PRRSV) with IC~50~ values of 68.9 ± 3.1 μM and 58.9 ± 10.2 μM, respectively \[[@B45-molecules-20-06715]\].

Chimonanthines were tested on μ- and κ-opioid binding assay, and on the tail-flick and the capsaicin-induced pain models. As a result, (−)-chimonanthine (**3**), (+)-chimonanthine (*ent*-**3**), and *meso*-chimonanthine (**11**) showed strong binding affinities towards μ-opioid receptors with *K*~i~ values of 271 ± 85 nM, 652 ± 159 nM, and 341 ± 29 nM, respectively, indicating their significant analgesic activities \[[@B46-molecules-20-06715],[@B47-molecules-20-06715]\].

It was also recently reported that the methanol extract of the flower buds of *Ch. praecox* showed an inhibitory effect against melanogenesis in ophylline-stimulated B16 melanoma 4A5 cells. A further investigation revealed that the principal alkaloids of (+)-calycanthine (**1**), (−)-chimonanthine (**3**), and (−)-folicanthine (**4**) showed the most potent melanogenesis inhibitory activity, with IC~50~ values of 0.93, 1.4, and 1.8 μM, respectively. Abutin (174 μM), a commercially tyrosinase inhibitor, was used as a positive control. In this paper, (+)-chimonanthine (*ent*-**3**), and *meso*-chimonanthine (**11**) showed cytotoxicity at 10 μM \[[@B41-molecules-20-06715]\]. In another assay, compounds **2**--**4** were screened for the cytotoxicity against a small panel of human cancer lines, showing cytotoxic effects against gastric carcinoma NUGC3 and hepatocarcinoma SNU739 cancer cells with IC~50~ values ranging from 10.3 to 19.7 μM \[[@B15-molecules-20-06715]\].

2.3. Biosynthetic Origins
-------------------------

Calycanthine, calycanthidine, chimonanthine, folicanthine, chimonanthidine, and CPC-2 are a series of tryptamine-derived dimeric alkaloids, which were proposed to be originated from *N*~b~-methyltryptamine (**15**). The oxidative dimerization of two molecules of *N*~b~-methyltryptamine forms the key tetraaminodialdehyde intermediate **16**, which undergoes several enzyme-catalyzed reactions and modifications yielding calycanthine and CPC-2 ([Scheme 1](#molecules-20-06715-f003){ref-type="fig"}) \[[@B39-molecules-20-06715]\]. A possible biosynthesis of chimonanmidine (**7**) is shown in [Scheme 2](#molecules-20-06715-f004){ref-type="fig"}. The intermediate **17** was derived from tryptamine (**12**) by oxidation, and subsequently converted into **18** by introduction a hydroxy function at the benzylic position. Chimonanmidine (**7**) was finally produced by the transannulation of the lactam ring of **18** \[[@B38-molecules-20-06715],[@B48-molecules-20-06715]\].

![Potential biogenetic pathway of tryptamine-derived dimeric Calycanthaceae alkaloids.](molecules-20-06715-g003){#molecules-20-06715-f003}

![Potential biogenetic pathway of chimonamidine (**7**).](molecules-20-06715-g004){#molecules-20-06715-f004}

3. Total Synthesis of Calycanthaceae Alkaloids
==============================================

3.1. Calycanthines and Chimonanthines
-------------------------------------

The dimeric piperidinoquinoline and pyrrolidinoindoline alkaloids have long been synthetic topics, and efforts have been made on the total synthesis of these two skeletons. Owing to their characteristic *C*~2~-symmetrical bridged bicycles and four chiral centers, three possible calycanthine diastereomers including (+)-calycanthine from Calycanthaceae plants, (−)- and *meso*-calycanthine from *Psychotria forsteriana* \[[@B29-molecules-20-06715]\], were identified ([Figure 2](#molecules-20-06715-f002){ref-type="fig"}). Likewise, the *C*~2~-symmetrical chimonanthines also comprised (±)- and *meso*-chimonanthine. The total syntheses of these alkaloids have been intensively studied for decades. Hino speculated that the structure of 1,1\'-dimethyl-3,3\'-bis(2-aminoethyl)-3,3\'-bioxindole was the key intermediate for the syntheses of calycanthine and (±)-folicanthine \[[@B49-molecules-20-06715],[@B50-molecules-20-06715]\]. Some other groups made synthetic efforts to these bis(pyrroloindoline) scaffold by oxidation dimerization of indole \[[@B51-molecules-20-06715]\] and/or oxindoles derivatives \[[@B52-molecules-20-06715],[@B53-molecules-20-06715]\]. The synthetic challenges were attributed to the two structural features of the dimeric pyrroloindole core, including C3a-C3\'a σ bond and its vicinal quaternary stereogenic carbons.

In 1964, Scott's group established an approach using *N*~b~-methyltryptamine (**15**) as starting material to form the magnesium salt of methyl tryptamine in presence of methyl magnesium iodide (CH~3~MgI). The intermediate was treated with iron(III) chloride to produce the indolenine dimer **19**, which was subsequently transformed to *meso*- and (±)-chimonanthine in one step. Moreover, (±)-calycanthine was accessible by treating (±)-chimonanthine with aqueous acid, demonstrating that structure of **1** was the thermodynamically preferred scaffold ([Scheme 3](#molecules-20-06715-f005){ref-type="fig"}) \[[@B54-molecules-20-06715]\].

![Structures of calycanthines.](molecules-20-06715-g002){#molecules-20-06715-f002}

![Biomimetic syntheses of chimonanthines and calycanthines proposed by Soctt.](molecules-20-06715-g005){#molecules-20-06715-f005}

![Stereocontrolled syntheses of *meso*-chimonanthine and *meso*-calycanthine by Overman.](molecules-20-06715-g006){#molecules-20-06715-f006}

Overman's group also proposed systemic syntheses for these Calycanthaceae alkaloids. In 1996, he attempted to stereocontrolly synthesize *meso*-chimonanthine (**11**) and *meso*-calycanthine (*meso*-**1**) via a samarium-mediated reductive dialkylation ([Scheme 4](#molecules-20-06715-f006){ref-type="fig"}). Isoindigo (**21**) was converted to *N*-benzyl derivative **22**, which then generated **24** by the treatment of 2 equiv. of SmI~2~ in the presence of 10 equiv. of LiCl with *cis*-1,4-dicholoro-2-butene. Compound **24** was subsequently transformed into hexacycle **25** with sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al). The cyclohexene of **25** was cleaved to yield **26**, which was immediately reduced to diamine **28** via diazide product **27**. Intermediate **28** was then treated with excess Me~3~Al at room temperature to provide bis(pyrroloindoline) **29**. The desired *meso*-chimonanthine (*meso*-**3**) was produced from **29** by a cascade of methylation and deprotection reactions. The final product *meso*-calycanthine (*meso*-**1**) was obtained by exposure of *meso*-**3** to hot dilute acetic acid \[[@B55-molecules-20-06715]\]. In 1999, a flexible approach to *meso*-chimonanthine ([Scheme 5](#molecules-20-06715-f007){ref-type="fig"}), (−)-chimonanthine, and (+)-calycanthine ([Scheme 6](#molecules-20-06715-f008){ref-type="fig"}) using an intramolecular Heck reaction cascade was present by Overman *et al.* \[[@B56-molecules-20-06715]\]. One year later, they put forward to a highly efficient synthesis of 3a,3a\'-bispyrrolidino\[2,3-*b*\]indolines, a precursor for the *meso*-chimonanthine ([Scheme 7](#molecules-20-06715-f009){ref-type="fig"}a) and (+)-chimonanthine ([Scheme 7](#molecules-20-06715-f009){ref-type="fig"}b). This dialkylation route utilized the reactivities of dienolate (chelated or nonchelated) and the chirality of a tartrate-derived dielectrophile to control the relative configuration and absolute stereochemistry, respectively \[[@B35-molecules-20-06715]\].

![Double Heck cyclizations for *meso*-chimonanthine by Overman.](molecules-20-06715-g007){#molecules-20-06715-f007}

In 2006, Dalko's group provided an elegant synthesis of a homologous compound of *meso*-chimonanthine, *N*~b~-desmethyl-*meso*-chimonanthine. They investigated a tandem \[4 + 2\]-cycloaddition-cyclisation of a conveniently functionalized bromoxidole (**55**) and tryptamine derivative **56** to construct the *meso*-chimonanthine core in a highly diastereoselective manner ([Scheme 8](#molecules-20-06715-f010){ref-type="fig"}) \[[@B57-molecules-20-06715]\].

![Double Heck cyclizations for (−)-chimonanthine and (+)-calycanthine by Overman.](molecules-20-06715-g008){#molecules-20-06715-f008}

In 2007, an alternative strategy for the total synthesis of (−)-calycanthine (*ent-***1**) and (+)-chimonanthine (*ent*-**3**) using a reductive Co^I^-promoted dimerization of *endo* bromide (+)-**60** was proposed by Movassaghi. The vital homodimerization requiring a stoichiometric amount of metal catalyst was the key step to secure the vicinal quaternary stereocenters, which was directed by the stereochemistry at the C8a-position of (+)-**60** ([Scheme 9](#molecules-20-06715-f011){ref-type="fig"}a). The further treatment of *ent*-**3** with \[D~4~\]acetic acid and deuterium oxide provided (−)-calycanthine (*ent*-**1**) ([Scheme 9](#molecules-20-06715-f011){ref-type="fig"}b) \[[@B58-molecules-20-06715]\]. In 2014, Movassaghi's group also described an enhanced diazene-based method for heterodimerization to enantioselectively synthesize the (−)-calycanthidine (**2**), *meso*-chimonanthine (**11**) and (±)-desmethyl-*meso*-chimonanthine (**58**) \[[@B59-molecules-20-06715],[@B60-molecules-20-06715]\].

![Enantioselective dialkylation approach for *meso*-chimonanthine (**a**) and (+)-chimonanthine (**b**) proposed by Overman.](molecules-20-06715-g009){#molecules-20-06715-f009}

![Synthesis of (±)-*N*~b~-desmethyl-*meso*-chimonanthine **(58)** via a tandem \[4 + 2\]-cycloaddition-cyclisation by Dalko.](molecules-20-06715-g010){#molecules-20-06715-f010}

![Synthesis of (+)-chimonanthine (*ent*-**3**) (**a**), (+)-folicanthine (*ent*-**4**) and (−)-calycanthine (*ent*-**1**) (**b**) via a reductive Co^I^-promoted homodimerization by Movassaghi.](molecules-20-06715-g011){#molecules-20-06715-f011}

In 2012, Kanai and Matsunaga's group illustrated a straightforward catalytic asymmetric total synthesis to achieve enantioselective (−)-calycanthine (*ent*-**1**) and (+)-chimonanthine (*ent*-**3**) in seven steps ([Scheme 10](#molecules-20-06715-f012){ref-type="fig"}). A one-pot double Michael reaction from 3,3\'-bioxindole **67** \[[@B61-molecules-20-06715]\] with the base catalyst Mn(4-F-BzO)~2~/Schiff (**69**) produced the key dialkylated adduct **71** in 69% yield and 95% *ee*. Then the intramolecular dicyclization of **72** was available by the treatment with LiEt~3~BH in toluene \[[@B62-molecules-20-06715]\]. Recently, a new strategy using a double intramolecular carbamoylketene-alkene \[2 + 2\] cycloaddition for the synthesis of the racemic chimonanthine was accomplished by Shishido's group (see Chapter 3.2) \[[@B63-molecules-20-06715]\].

3.2. Folicanthines
------------------

The structures of the folicanthines are also representatives of the dimeric hexahydropyrroloindole alkaloid family. (+)-Folicanthine (*ent*-**4**) could be easily obtained in a quantitative yield from (+)-chimonanthine (*ent*-**3**) by treatment with formaldehyde and sodium triacetoxyborohydride \[NaBH(OAc)~3~\] ([Schemes 9](#molecules-20-06715-f011){ref-type="fig"}b and [scheme10](#molecules-20-06715-f012){ref-type="fig"}) \[[@B58-molecules-20-06715],[@B62-molecules-20-06715]\]. In striking contrast to the elegant synthetic procedures towards calycanthines and chimonanthines, Gong's group have developed a highly enantioselective nucleophilic substitution reaction of 3-hydroxyoxindoles with an enecarbamate catalyzed by chiral phosphoric acids.

![Synthesis of (+)-chimonanthine (*ent*-**3**), (+)-folicanthine (*ent*-**4**) and (−)-calycanthine (*ent*-**1**) via double Michael reaction of bisoxindole by Matsunaga.](molecules-20-06715-g012){#molecules-20-06715-f012}

In [Scheme 11](#molecules-20-06715-f013){ref-type="fig"}, the vital enantioselective substitution reaction of 3-hydroxy-3,3\'-bisindolin-2-one (**73**) with **75** was catalyzed by a special chiral phosphoric acids **74** to give **76**. The dimethylation of **76** provided **77**, which was followed with a Beckmann rearrangement to convert the ketones into amide derivatives **78a** and **78b**. A second Beckmann rearrangement of **78b** by the treatment with mercury(II) chloride (Hg~2~Cl) could furnish amide **79**. After introducing a methyl group at the amide nitrogen atom, the product **80** underwent an alkylation to produce key intermediate **81**, which was finally converted to the desired product (+)-folicanthine (*ent*-**4**) after several step sequences \[[@B64-molecules-20-06715]\]. Contemporaneously, Liang's group described a concise three-step synthesis of (±)-folicanthine using two molecules of 2-(1-methyl-1*H*-indole-3-yl)-*N*-tosylethaneamine (**84**, [Scheme 12](#molecules-20-06715-f014){ref-type="fig"}). The core structure **85** of (±)-folicanthine could be easily obtained by a one-step cyclization-dimerization of substituted tryptophan in high yield. In general, this synthetic route had the advantages of being highly efficient, atom-economic, and metal-free, but it has no enantioselectivity \[[@B65-molecules-20-06715]\]. Recently, Shishido's group also developed a total synthesis route to access the folicanthines and chimonanthines in racemic form, employing a double intramolecular carboamoylketene-alkene \[2 + 2\] cycloaddition reaction as the key step ([Scheme 13](#molecules-20-06715-f015){ref-type="fig"}). 2,2\'-(Buta-1,3-diene-2,3-diyl)bis(nitrobenzene) (**90**), obtained by a Pd-catalyzed preparation, underwent the key double \[2 + 2\] cycloaddition to yield bis-carboxylic acid **92**. After a three-step sequence, the mixture of (±)-folicanthine and *meso*-folicanthine (*meso-***4**) was obtained, which was separated by preparative TLC in 36% and 20% yields, respectively \[[@B63-molecules-20-06715]\].

![Synthesis of (+)-folicanthine (*ent*-**4**) via asymmetric organocatalytic substitution reaction by Gong.](molecules-20-06715-g013){#molecules-20-06715-f013}

![Concise synthesis of (±)-folicanthine by Liang.](molecules-20-06715-g014){#molecules-20-06715-f014}

![Synthesis of folicanthines and (±)-chimonanthine via a double intramolecular carbamoylketene-alkene \[2 + 2\] cycloaddition by Shishido.](molecules-20-06715-g015){#molecules-20-06715-f015}

3.3. (−)-Idiospermuline (**6**)
-------------------------------

(−)-Idiospermuline (**6**), a typical trispyrrolidinoindoline alkaloid, contains three all-carbon quaternary centers, consisting of one (−)-chimonanthine unit and one pyrrolidinoindoline unit with a C3\'\'a--C7\' σ bond. Its retrosynthetic analysis was similar to that of hodgkinsines \[[@B66-molecules-20-06715]\] and is presented in [Scheme 14](#molecules-20-06715-f016){ref-type="fig"}, which guided the total enantioselective synthesis of (−)-idiospermuline ([Scheme 15](#molecules-20-06715-f017){ref-type="fig"}). The first step in the synthesis focused on the dimeric pyrrolidinoindoline derivative **97** similar to that of (+)-chimonanthine in [Scheme 7](#molecules-20-06715-f009){ref-type="fig"}. The introduction of the readily available stannyl butenanilide **102** furnished the intermediate **96**. Heck cyclization of **96** treating with chelating diphosphane ligands like bis(1,4-diphenylphosphanyl)butane (dppb) diastereoselectively furnished 3a\'\'*R* precursor **95**. Catalytic hydrogenation of 95 with Pd(OH)~2~ and H~2~, followed by reduction of the carbonyl group with Red-Al in toluene, then Na in NH~3~, provided the desired (−)-idiospermuline (**6**) \[[@B67-molecules-20-06715],[@B68-molecules-20-06715],[@B69-molecules-20-06715],[@B70-molecules-20-06715]\].

![Retrosynthesis of (−)-idiospermuline (**6**).](molecules-20-06715-g016){#molecules-20-06715-f016}

![Total synthesis of (−)-idiospermuline (**6**).](molecules-20-06715-g017){#molecules-20-06715-f017}

3.4. Chimonamidines (**7**)
---------------------------

Takayama's group conducted a biomimetic synthesis ([Scheme 16](#molecules-20-06715-f018){ref-type="fig"}) in order to confirm the absolute structure of chimonamidine (**7**). Based on its plausible biogenetic pathway shown in [Scheme 2](#molecules-20-06715-f004){ref-type="fig"}, the precursor *N*~a~,*N*~b~-dimethyltryptamine (**13**) was treated with benzyl chloroformate (Cbz-Cl) and Na~2~CO~3~ to give *N*~a~,*N*~b~-dimethyl-*N*~b~-carbobenzyloxytryptamine (**103**). Oxidation of **103** with dimethyl sulfoxide and hydrochloric acid yielded **104**, which was then converted to the racemic mixture of (±)-hydroxyketones **105** by introduction of a hydroxy group at the benzylic position. The target racemic mixture of (±)-chimonamidine (**7**) was obtained by removing the *N*~b~-Cbz protecting group and forming a new lactam ring under the condition of trimethylsilyl iodide (TMSI). Meanwhile, the chiral synthesis of chimonamidine was also performed by Takayama. After several attempts, a strategy that involved the separation of racemic mixtures by (+)-MTPA chloride and SiO~2~ column chromatography succeeded to yield two diastereomeric esters **106** and **107**. Two more steps that involved the hydrolysis with aqueous alkaline solution and cyclization with TMSI of **106** and **107** were conducted to afford two enantiomerically pure compounds (*R*)-(−)-chimonamidine and (*S*)-(+)-chimonamidine, respectively. A comparison of the optical rotation between synthesized ($\left\lbrack \alpha \right\rbrack_{D}^{23}$ = −178 for (*R*)-(−)-**7**; $\left\lbrack \alpha \right\rbrack_{D}^{23}$ = +171 for (*S*)-(+)-**7**) and natural chimonamidine ($\left\lbrack \alpha \right\rbrack_{D}^{19}$ = −12.6) came to the conclusion that natural chimonamidine was a mixture slightly enriched with (*R*)-(−)-chimonamidine \[[@B38-molecules-20-06715]\].

![Total synthesis of (±)-chimonamidine (**7**).](molecules-20-06715-g018){#molecules-20-06715-f018}

3.5. Chimonanthidine (**8**)
----------------------------

A synthetic approach that uses hypervalent iodine(III) reagents for the dimerization of indole derivatives was developed for the total synthesis of (±)-chimonanthidine (**8**) by Takayama's group ([Scheme 17](#molecules-20-06715-f019){ref-type="fig"}). The methylation of the known compound **108** with methyl iodide (CH~3~I) and sodium hydride (NaH) in DMF produced *N*~a~-Methyl-*N*~b~-trimethylsilyethoxy-carbonyl (Teoc) tryptamine (**109**), which was then treated with 0.5 equiv. phenyliodine(III) bis(trifluoroacetate) (PIFA) in CF~3~CH~2~OH to yield two dimeric diastereoisomers **110** and **111**. (±)-Chimonanthidine (**8**) was obtained from the monodeprotected amine **112**, which was transformed from **111** by treatment with tetrabutylammonium fluoride (TBAF) in THF \[[@B38-molecules-20-06715]\].

![Total synthesis of (±)-chimonanthidine (**8**).](molecules-20-06715-g019){#molecules-20-06715-f019}

3.6. Rac-CPC-1 (Rac-**9**)
--------------------------

The total synthesis of racemic CPC-1 was initially performed to confirm the structure of CPC-1 ([Scheme 18](#molecules-20-06715-f020){ref-type="fig"}). Compound **113** was treated with *m*-CPBA in the presence of excess trifluoroacetic acid (TFA) in CH~2~Cl~2~ to afford 3a-hydroxypyrrolidinoindoline (**114**). Methylation of the hydroxy group of **114** and then removal of the *N*~b~-Teoc group yielded the intermediate **115**, which was finally treated with formalin and then NaBH~3~CN to give *rac*-**9**. To further establish the absolute configuration of **9**, its chiral total synthesis was conducted ([Scheme 19](#molecules-20-06715-f021){ref-type="fig"}). This synthetic approach started from isatin (**66**), which was treated with (*R*)-(+)-binol, Ti(O*^i^*Pr)~4~, and tetraallylstannane to yield allylated compound **116**. Two recrystallizations of **116** from EtOAc afford enantiomerically pure (*S*)-(−)-**116**. Methylations of *N*~a~ and hydroxy group of (*S*)-(−)-**116** gave the dimethyl compound **117**. The intermediate **117** was treated with OsO~4~ and *N*-methylmorpholine *N*-oxide (NMO) followed by NaIO~4~ to provide the aldehyde, which was directly subjected to reductive amination by condensing with CH~3~NH~2~ and then reduced with NaBH~3~CN to give (*S*)-(−)-**118**. The desired product (3a*S*, 8a*S*)-**9** was obtained by the reductive cyclization of **118**. The optical rotation value of (3a*S*, 8a*S*)-**9** ($\left\lbrack \alpha \right\rbrack_{D}^{24}$ = +101) was determined to be opposite of that of **9** ($\left\lbrack \alpha \right\rbrack_{D}^{24}$ = −88), indicating the absolute configuration of natural CPC-1 to be 3a*R*,8a*R* \[[@B39-molecules-20-06715]\].

![Total synthesis of *rac*-**9**.](molecules-20-06715-g020){#molecules-20-06715-f020}

![Total synthesis of (3a*S*, 8a*S*)-**9**.](molecules-20-06715-g021){#molecules-20-06715-f021}

4. Conclusions
==============

In conclusion, the Calycanthiaceae plants are rich in promising bioactive dimeric and/or oligomeric piperidinoquinoline and hexahydropyrroloindole alkaloids, which are characterized by unique vicinal quaternary stereocenters. These alkaloids have been a longstanding challenge as total synthetic targets. During the last decades, stereocontrolled total synthetic approaches, such as metal-catalyzed dialkylation, intramolecular double Heck reaction, tandem \[4 + 2\]-cycloaddition-cyclisation, Co^I^-promoted reductive homodimerization, double Michael reaction, double Beckmann rearrangement, and intramolecular double carbamoylketene-alkene \[2 + 2\] cycloaddition, have extensively explored. Taken together, these results will keep research on the metabolites of the Calycanthaceae plants as a hot topic for the scientific community in the future.
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Ac

:   acetyl

Bn

:   benzyl

Boc

:   *tert*-butoxycarbonyl

CAN

:   ceric ammonium nitrate

CAS

:   camphorsulfonic acid monohydrate

Cbz

:   carbobenzoxy

*m*-CPBA

:   *m*-cholorperoxybenzoic acid

dba

:   *trans,trans*-dibenzylideneacetone

dppe

:   1,2-bis(diphenylphosphino)ethane

dppb

:   bis(1,4-diphenylphosphanyl)butane

DMA

:   *N,N*-dimethylacetamide

DMF

:   2,5-dimethylfuran

DMSO

:   dimethyl sulfoxide

2,2-DMP

:   2,2-dimethioxypropane

DMPU

:   1,3-dimethylhexahydro-2-pyrimidinone

HMDS

:   1,1,1,3,3,3-hexamethyldisilazane

HMPA

:   hexamethylphoramide

NaHMDS

:   sodium hexamethyldisilazide

NMO

:   4-methylmorpholine-*N*-oxide

PIFA

:   phenyliodine(III) bis(trifluoroacetate)

PMP

:   1,2,2,6,6-pentamethylpiperidine

PSTA

:   *p*-toluenesulfonic acid

Red-Al

:   sodium bis(2-methoxyethoxy)aluminum hydride

TBAF

:   tertrabutylammonium fluoride

Tf

:   trifluoromethanesulfonyl

TFA

:   trifluoroacetic acid

THF

:   tetrahydrofuran

TMEDA

:   *N,N,N,N*-tetramethylethylenediamine

TMS

:   trimethylsilyl
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